# Dror Ortho-Design, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Dror Ortho-Design, Inc.). ## Overview Dror Ortho-Design, Inc. develops an AI-based orthodontic platform designed to correct smiles with less lifestyle disruption than traditional clear aligners. The company’s core product, ZSmile, uses a single smart aligner and pulsating air while the patient sleeps or stays at home, and it is positioned as a dentist-controlled alternative in the smile-correction market. ## Products & services • ZSmile nighttime orthodontic platform • Aerodentis first-generation aligner system • AI-based treatment planning and monitoring software • Proprietary orthodontic device hardware and aligners • Regulatory, IP, and clinical commercialization support - **Orthodontic treatment platform** (70%) — The ZSmile system and related orthodontic device platform used to move teeth discreetly during sleep or at home. - **Legacy aligner system** (10%) — The earlier Aerodentis solution that remains part of the company’s technology history and product lineage. - **Treatment software** (10%) — Software used to plan, monitor, and support dentist-controlled orthodontic treatment workflows. - **Regulatory and IP-enabled commercialization** (10%) — Activities tied to FDA clearance, patent protection, and product readiness for market launch. - ZSmile nighttime orthodontic platform - Aerodentis first-generation aligner system - AI-based treatment planning and monitoring software - Proprietary orthodontic device hardware and aligners - Regulatory, IP, and clinical commercialization support ## Customers The company’s target customers are dental professionals, especially general practice dentists and orthodontists who would prescribe and monitor treatment using the platform. Its end users are patients seeking smile correction with less inconvenience than conventional aligners, but the commercial buyer and treatment decision-maker is the dental professional. The company also competes for adoption against clear aligner alternatives, so customer value depends on clinical utility, convenience, and pricing. - **General practice dentists** (primary) — They buy or recommend the platform to expand orthodontic services without relying only on orthodontists. - **Orthodontists** (primary) — They use the system for smile correction treatment planning and patient monitoring. - **Patients / consumers** (primary) — They ultimately choose the treatment because the product promises discreet, lower-disruption smile correction. - **Dental practices and clinics** (secondary) — They adopt the platform to add orthodontic capability and differentiate their service offering. - General practice dentists who want to offer orthodontic treatment - Orthodontists who need an alternative to standard clear aligners - Patients seeking discreet smile correction with less lifestyle disruption - Dental practices that value dentist-controlled treatment workflows - Consumers comparing ZSmile against clear aligner brands ## Geography The company is headquartered in the United States and reports in U.S. dollars, but its operating history includes Israeli roots through Dror Ortho-Design Ltd. The filings do not disclose a country revenue split, which suggests the business is still in development and not yet commercially scaled across geographies. Its near-term geographic exposure is therefore tied more to U.S. regulatory approval and commercialization than to a broad international sales footprint. - Headquartered in the United States - Historical operating roots in Israel through predecessor Dror Ortho-Design Ltd. - U.S. FDA clearance is central to commercialization - No country-level revenue split disclosed in the filings - Current exposure is mainly U.S. market development and launch ## Strategy Management is focused on commercializing ZSmile, protecting the underlying intellectual property, and expanding the addressable practitioner base beyond orthodontists to general dentists. The company is also prioritizing financing because it remains in development stage and needs capital to support product development, regulatory work, and market entry. - **Commercialize ZSmile** (short-term) — The company needs a marketable product to move from development stage to revenue generation. - **Broaden practitioner adoption** (medium-term) — Selling through general dentists expands the reachable market beyond orthodontists. - **Protect intellectual property** (medium-term) — Patent and trade secret protection are important to defend the technology against larger competitors. - **Secure financing** (short-term) — The company is loss-making and needs capital to continue development and commercialization. - Commercialize ZSmile as a discreet nighttime orthodontic solution - Expand adoption from orthodontists to general practice dentists - Protect patents, trademarks, and trade secrets around the platform - Use FDA clearance to support U.S. commercialization - Raise capital to fund development and launch activities ## Risks The company is an early-stage medical device business with no current revenue, so its ability to continue as a going concern depends on raising additional capital and successfully commercializing the platform. It also faces execution risk in product development, regulatory compliance, supply chain reliability, and competition from much larger aligner brands and teledentistry alternatives. - **Need for additional financing** [critical] — The company is not generating revenues and must fund development and operations externally. - **Failure to achieve market acceptance** [high] — The platform must convince dentists and patients to switch from established aligner solutions. - **Competition from established aligner brands** [high] — Large competitors have stronger channels, brand recognition, and resources. - **Product development and regulatory execution** [high] — The platform is a Class II medical device and commercialization depends on successful development and compliance. - **Business disruption and supply chain issues** [medium] — Delays or shortages could interrupt R&D, manufacturing, and future deliveries. - Going-concern risk because the company needs additional capital - Commercialization risk if ZSmile fails to gain market acceptance - Competition from large aligner and orthodontic companies - Regulatory and product-development risk for a medical device platform - Operational and supply-chain disruption risk during scale-up ## Accounting The company’s accounting is dominated by development-stage judgments rather than revenue recognition, since it currently does not generate revenues. Investors should watch how research and development costs are expensed, how going-concern assumptions affect the financial statements, and how estimates around financing, deferred revenue, and future commercialization are applied as the business scales. - **Research and development expensed as incurred** — Affects operating loss and comparability across periods - **Going-concern assessment** — Important for liquidity disclosure and investor risk assessment - **Deferred revenue estimates** — Could affect timing of revenue recognition and margins - **No derivatives or off-balance-sheet arrangements** — Limits exposure to fair value and hedge accounting issues - R&D is expensed as incurred, affecting reported losses - Going-concern assessment reflects dependence on future financing - Deferred revenue estimates could matter once sales begin - No derivative contracts or off-balance-sheet arrangements disclosed - Future commercialization may increase judgment around capitalization and impairment --- *Last updated: 2026-04-28T20:02:22.991394+00:00*